BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 15880234)

  • 1. The influence of occult infection with hepatitis B virus on liver histology and response to interferon treatment in chronic hepatitis C patients.
    Silva Cd; Gonçales NS; Pereira JS; Escanhoela CA; Pavan MH; Gonçales FL
    Braz J Infect Dis; 2004 Dec; 8(6):431-9. PubMed ID: 15880234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C.
    Fabris P; Brown D; Tositti G; Bozzola L; Giordani MT; Bevilacqua P; de Lalla F; Webster GJ; Dusheiko G
    J Clin Virol; 2004 Mar; 29(3):160-6. PubMed ID: 14962784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
    Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
    J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occult hepatitis B infection in Portuguese patients with chronic hepatitis C liver disease: prevalence and clinical significance.
    Cardoso C; Alves AL; Augusto F; Freire R; Quintana C; Gonçalves M; Oliveira AP
    Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):142-6. PubMed ID: 23044809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin.
    Levast M; Larrat S; Thelu MA; Nicod S; Plages A; Cheveau A; Zarski JP; Seigneurin JM; Morand P; Leroy V
    J Med Virol; 2010 May; 82(5):747-54. PubMed ID: 20336715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of previous HBV infection on the course of chronic hepatitis C.
    De Maria N; Colantoni A; Friedlander L; Leandro G; Idilman R; Harig J; Van Thiel DH
    Am J Gastroenterol; 2000 Dec; 95(12):3529-36. PubMed ID: 11151889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of occult HBV infection in patients with chronic hepatitis C.
    Anwar W; Sarwar M; Hussain AB; Tariq WU; Saif M
    J Coll Physicians Surg Pak; 2006 Mar; 16(3):192-5. PubMed ID: 16542598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients.
    Laguno M; Larrousse M; Blanco JL; Leon A; Milinkovic A; Martínez-Rebozler M; Loncá M; Martinez E; Sanchez-Tapias JM; de Lazzari E; Gatell JM; Costa J; Mallolas J
    AIDS Res Hum Retroviruses; 2008 Apr; 24(4):547-53. PubMed ID: 18393687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C.
    Mrani S; Chemin I; Menouar K; Guillaud O; Pradat P; Borghi G; Trabaud MA; Chevallier P; Chevallier M; Zoulim F; Trépo C
    J Med Virol; 2007 Aug; 79(8):1075-81. PubMed ID: 17596829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
    Khattab E; Chemin I; Vuillermoz I; Vieux C; Mrani S; Guillaud O; Trepo C; Zoulim F
    J Clin Virol; 2005 Jun; 33(2):150-7. PubMed ID: 15911431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.
    Cacciola I; Pollicino T; Squadrito G; Cerenzia G; Orlando ME; Raimondo G
    N Engl J Med; 1999 Jul; 341(1):22-6. PubMed ID: 10387938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of occult hepatitis B virus infection in chronic hepatitis C patients.
    Jang JY; Jeong SW; Cheon SR; Lee SH; Kim SG; Cheon YK; Kim YS; Cho YD; Kim HS; Jin SY; Kim YS; Kim BS
    Korean J Hepatol; 2011 Sep; 17(3):206-12. PubMed ID: 22102387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C.
    Uyanikoglu A; Akyuz F; Baran B; Simsek BP; Ermis F; Demir K; Gulluoglu M; Badur S; Kaymakoglu S
    Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):485-90. PubMed ID: 23665172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Previous Exposure to HBV on Liver Histology and Treatment Response in CHC Patients.
    Khan HA; Umar M; Hamama-tul-Bushra ; Ahmed M; Ambreen S
    J Coll Physicians Surg Pak; 2015 Jul; 25(7):498-500. PubMed ID: 26208552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of hepatitis B virus integration into liver tissue on the efficacy of peginterferon and ribavirin therapy in hepatitis B virus-negative chronic hepatitis C patients.
    Toyoda H; Kumada T; Tada T; Murakami Y
    J Clin Gastroenterol; 2014 Jan; 48(1):73-9. PubMed ID: 23842217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C.
    Myers RP; Thibault V; Poynard T
    J Viral Hepat; 2003 Mar; 10(2):103-10. PubMed ID: 12614466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C virus-positive patients.
    Giannini E; Ceppa P; Botta F; Fasoli A; Romagnoli P; Ansaldi F; Durando P; Risso D; Lantieri PB; Icardi GC; Testa R
    Liver Int; 2003 Feb; 23(1):12-8. PubMed ID: 12640722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.